<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00062179</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000304540</org_study_id>
    <secondary_id>UCLA-0208074</secondary_id>
    <secondary_id>NYH-CMC-0902-464</secondary_id>
    <secondary_id>PHARMACIA-COXAON-0509-106</secondary_id>
    <nct_id>NCT00062179</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Double Blind Phase II Study of Preoperative Celecoxib/Paclitaxel/Carboplatin for Stage IIIA Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmacia</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as paclitaxel and carboplatin use different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Celecoxib may increase the&#xD;
      effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug, may&#xD;
      stop the growth of tumor cells by stopping blood flow to the tumor, and/or may block the&#xD;
      enzymes necessary for tumor cell growth. Giving combination chemotherapy with celecoxib&#xD;
      before surgery may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well giving paclitaxel together with&#xD;
      carboplatin followed by surgery works compared to giving paclitaxel together with carboplatin&#xD;
      and celecoxib followed by surgery in treating patients with stage IIIA non-small cell lung&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the complete pathological response rate and/or minimal residual microscopic&#xD;
           disease in patients with stage IIIA non-small cell lung cancer treated with preoperative&#xD;
           paclitaxel and carboplatin with vs without celecoxib.&#xD;
&#xD;
        -  Compare the clinical response rate in patients treated with these regimens.&#xD;
&#xD;
        -  Compare chemotherapy-related toxicity in patients treated with these regimens.&#xD;
&#xD;
        -  Compare the time to progression, disease-free survival, and overall survival of patients&#xD;
           treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified&#xD;
      according to use of aspirin for prior cardiovascular disease (yes vs no). Patients are&#xD;
      randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 1 hour on&#xD;
           days 1, 22, and 43. Patients also receive oral celecoxib twice daily beginning on day 1&#xD;
           and continuing until the morning of surgical resection.&#xD;
&#xD;
        -  Arm II: Patients receive paclitaxel and carboplatin as in arm I and an oral placebo&#xD;
           twice daily beginning on day 1 and continuing until the morning of surgical resection.&#xD;
&#xD;
      In both arms, patients undergo surgical resection and complete mediastinal lymph node&#xD;
      dissection within 3-6 weeks after completion of chemotherapy. Patients resume oral celecoxib&#xD;
      or placebo twice daily within 28-42 days after surgery and continue until 3 years from the&#xD;
      date of randomization in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3-6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 110 patients (55 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of complete pathological response and/or minimal residual microscopic disease at 3 years</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in time to progression, disease-free survival, and overall survival between Arm I and Arm II at 3 years</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity in patients with paclitaxel/carboplatin/celecoxib vs. paclitaxel/carboplatin/placebo</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>paclitaxel/carboplatin/celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Celecoxib: 400 mg po BID 3 cycles of paclitaxel and carboplatin 21 days apart celecoxib 3-7 days before first dose of chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>paclitaxel/Carboplatin/Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion Carboplatin: dosed at an AUC of 6 by the Calvert Formula Placebo 3 cycles of paclitaxel and carboplatin 21 days apart Placebo 3-7 days before first dose of chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart</description>
    <arm_group_label>paclitaxel/Carboplatin/Placebo</arm_group_label>
    <arm_group_label>paclitaxel/carboplatin/celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy</description>
    <arm_group_label>paclitaxel/carboplatin/celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart</description>
    <arm_group_label>paclitaxel/Carboplatin/Placebo</arm_group_label>
    <arm_group_label>paclitaxel/carboplatin/celecoxib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo 3-7 days before first dose of chemotherapy</description>
    <arm_group_label>paclitaxel/Carboplatin/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with biopsy proven non-small cell lung cancer clinical stage IIIA&#xD;
&#xD;
          -  Mediastinoscopy positive N2 disease is mandatory&#xD;
&#xD;
          -  The disease must be deemed potentially resectable by the thoracic surgeon&#xD;
&#xD;
          -  Karnofsky performance status &gt; 80%&#xD;
&#xD;
          -  Pulmonary function must be acceptable for surgery according to institutional standards&#xD;
&#xD;
          -  Acceptable hepatic, renal and bone marrow function&#xD;
&#xD;
               -  Total serum bilirubin &lt; ULN&#xD;
&#xD;
               -  AST and/or ALT &lt; 2.5x ULN&#xD;
&#xD;
               -  Alkaline phosphatase &lt; 2.5x ULN&#xD;
&#xD;
               -  Serum creatinine &lt; 2.0 mg/mm3&#xD;
&#xD;
               -  White blood cell &gt; 3000/mm3&#xD;
&#xD;
               -  Platelets &gt; 100,000/mm3&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Willingness to abstain from chronic use of NSAIDs (defined as &gt; 7 days of continuous&#xD;
             therapy per month OR defined as frequency of &gt; 3 times per week) for the duration of&#xD;
             the study. For those patients on NSAIDs prior to study entry, cessation of the drug&#xD;
             for 72 hours prior to study entry is required&#xD;
&#xD;
          -  Patients on low-dose ASA (&lt;325 mg daily) for prophylaxis of cardiovascular disease&#xD;
             prior to study entry may remain on that dose of ASA during this trial&#xD;
&#xD;
          -  No anticipated chronic use of steroids. Patients may take the inhaled steroids&#xD;
             mometasone or fluticasone if medically indicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known hypersensitivity or allergic reactions to COX-2 inhibitors,&#xD;
             sulfonamides, NSAIDs, or salicylates&#xD;
&#xD;
          -  Hypersensitivity to paclitaxel&#xD;
&#xD;
          -  Significant medical or psychiatric illness that would interfere with patient&#xD;
             compliance&#xD;
&#xD;
          -  Prior malignancy within the last 3 years with the exception of non-melanoma skin&#xD;
             cancer&#xD;
&#xD;
          -  Receiving other investigational agents during the course of this study or are &lt; 3&#xD;
             weeks from completion of other clinical trial therapy&#xD;
&#xD;
          -  Patients with a history of peptic ulcer disease, bleed disorder, irritable bowel&#xD;
             disease, inflammatory bowel syndrome, chronic diarrhea or bowel obstruction within 5&#xD;
             years&#xD;
&#xD;
          -  Patients receiving enzyme-inducing anticonvulsants are ineligible. Patients who&#xD;
             require concomitant therapy with NSAIDs or COX-2 inhibitors&#xD;
&#xD;
          -  Patients with any other serious underlying medical condition that would impair the&#xD;
             ability of the patient to receive or comply with protocol treatment&#xD;
&#xD;
          -  Patients receiving lithium or fluconazole&#xD;
&#xD;
          -  Pregnant women or women of childbearing potential that refuse to use effective&#xD;
             contraception during the period of chemotherapy.&#xD;
&#xD;
          -  Patients with a significant history of unstable cardiovascular disease&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or&#xD;
             interstitial pneumonia or interstitial fibrosis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Rickard</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Weill Cornell Cancer Center at Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>June 5, 2003</study_first_submitted>
  <study_first_submitted_qc>June 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2003</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

